Related Experiment Video
Updated: Apr 30, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
1.0K
Summary
The PI3Kδ inhibitor idelalisib showed effectiveness in patients with mantle cell lymphoma who had undergone extensive prior treatments. This finding offers a new therapeutic option for this challenging patient group.
Area of Science:
- Oncology
- Pharmacology
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma.
- Patients with relapsed or refractory MCL often have limited treatment options.
Purpose of the Study:
- To evaluate the efficacy of the PI3Kδ inhibitor idelalisib in heavily pretreated MCL patients.
Main Methods:
- Clinical trial evaluating idelalisib in patients with relapsed/refractory MCL.
- Assessment of treatment response and adverse events.
Main Results:
- Idelalisib demonstrated significant effectiveness in heavily pretreated MCL patients.
- The drug was generally well-tolerated in this patient population.
Conclusions:
- Idelalisib represents a promising therapeutic strategy for patients with advanced mantle cell lymphoma.
- Further investigation is warranted to optimize its use in MCL treatment paradigms.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
10.3K
08:38Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
Published on: October 4, 2018
20.8K
